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grades ($272), however, the differences in expenditures were not
statistically signiﬁcant. No statistically signiﬁcant differences
were detected in the health care expenditures among categories
of other variables but this may be due partly to the relatively
small sample size. CONCLUSION: Gender and family size
appeared to play a role on the magnitude of health care expen-
ditures among dermatophytosis patients.
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OBJECTIVES: This study examined the relationship between
depressive symptoms and related medication adherence and
health care costs in older adults (age ≥ 65 years) with psoriasis.
METHODS: This was a prospective longitudinal cohort study
over a 2-year post enrollment period in a population of older
adults with psoriasis enrolled in a Medicare Health Maintenance
Organization (HMO) in southeastern United States with pre-
scription beneﬁts. Upon enrollment, each enrollee was mailed a
comprehensive health status assessment battery, which included
the Center for Epidemiologic Studies Depression (CES-D) scale.
Information on medication adherence (using medication posses-
sion ratio) and total health care utilization/costs following enroll-
ment were retrieved from the Medicare HMO database.
Sixty-three older adults with psoriasis using topical corticos-
teroids therapy and enrolled in the Medicare HMO for a 2 year
continuous period were included in the ﬁnal sample. RESULTS:
Nearly one-ﬁfths of the patient population had depressive symp-
toms. Patients with psoriasis who had depressive symptoms at
the time of enrollment were less likely to be adherent to topical
corticosteroid medication (Spearman rho = -0.29, p < 0.01) and
less likely to utilize health care resources as evidenced by lower
health care costs (Spearman rho = -0.27, p < 0.05), after con-
founder adjustment. CONCLUSIONS: The prevalence of
depressive symptoms in older adults with psoriasis is common-
place, with strong, yet unexplained correlations between pres-
ence of depressive symptoms and lower rates of medication and
health care service use among these patients.
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OBJECTIVES: To determine if the quality-of-life of AMD
patients with monocular visual dysfunction differs from that of
those with bilateral visual dysfunction. METHODS: A cross-
sectional study (n = 168) determined if there was a statistically
signiﬁcant difference in patient-reported health related quality-
of-life (HRQoL) of AMD patients with monocular versus 
bilateral visual dysfunction. Subjects underwent a series of 
interviewer-administered techniques to ascertain their HRQoL,
including the Visual Function Index (VF-14) and patient prefer-
ences elicited through both the time tradeoff (TTO) and stan-
dard reference gamble (SRG). Visual acuity obtained from a
subject’s better- and worse-seeing eye was categorized as 20/20
to 20/40, 20/40–20/70, 20/80–20/200, and worse than 20/200.
Based on the various combinations of these 4 visual acuity
groupings in the better-seeing (BSE) and worse-seeing eyes
(WSE), subjects were classiﬁed into one of 10 subgroups. Mul-
tivariate linear regression determined if an association existed
between various clinical variables and HRQoL. RESULTS: The
mean age was 72 years; 63% were females. Mean scores were:
VF-14, 66.1; TTO, 0.86; SRG, 0.89. Subjects with binocular
visual dysfunction reported a lower HRQoL compared to those
with monocular dysfunction (p < 0.001); mean differences in the
TTO, SRG, and VF-14 were 0.19 (SE = 0.04), 0.14 (SE = 0.04),
and 59.2 (SE = 3.9), respectively. Multivariate models demon-
strated that only visual acuity subgrouping, a function of acuity
in both the BSE and WSE, was associated with HRQoL score
(overall eta2 = 34.8%, p < 0.01, and partial eta2 equal to 22%
[TTO], 20% [SRG] and 60% [VF-14]). Models including both
BSE and WSE visual acuity explained an additional 10% in
HRQoL variability compared to models with only BSE visual
acuity. CONCLUSIONS: Subjects with binocular visual dys-
function reported a signiﬁcantly lower HRQoL as compared to
those with monocular dysfunction. These results suggest that
binocular vision is a better predictor of HRQoL in AMD than
only visual acuity in the BSE.
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OBJECTIVE: The lack of speciﬁc ICD-9 codes and under self-
reporting and diagnosis of ChHD suggests a need for a self-
assessment survey to identify ChHD. This pilot study was
conducted to validate a newly designed self-assessment ques-
tionnaire and the Skindex-29 QoL instrument for use by ChHD
patients. METHODS: A clinical questionnaire, consisting of 16
questions, was developed to identify patients with ChHD and to
assess its severity, through patient self-administration. Sensitiv-
ity, speciﬁcity, and receiver operating characteristic (ROC) curve
were used to evaluate how closely the ChHD diagnosis based on
self-assessment concurred with physician’s diagnoses. Also,
Skindex-29, a QoL instrument with 29 questions not previously
validated in a ChHD population, was evaluated for internal con-
sistency and construct validity for ChHD patients in this study.
Forty-patients (ChHD n = 20; other skin disorders n = 20), with
a mean age of 46.6 ± 14.8 years and 30% males, were randomly
selected from a dermatology clinic in Louisville, Kentucky for
this pilot study. RESULTS: The performance of the clinical ques-
tionnaire matched the physicians’ diagnosis in identifying ChHD
with a sensitivity of 85%, a speciﬁcity of 95%, and an area under
the ROC curve of 0.83. The internal consistency of the Skindex-
29 was higher than that reported previously in a general der-
matology population, with a Cronbach alpha of 0.77 to 0.94 for
3 different (symptoms, emotions and functioning) domains. The
construct validity of Skindex-29 was evaluated by examining the
correlation between the overall score and physician’s assessment
of ChHD severity. The Pearson rho was 0.55 (p = 0.07), slightly
lower than that reported previously, but higher than that
reported for other QoL instruments. CONCLUSIONS: This
study indicates that the newly developed ChHD self-assessment
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instrument and the Skindex-29 questionnaire appear to have rea-
sonable performance and validity for ChHD patients. Further
validation studies with a larger sample size will be needed to
conﬁrm these ﬁndings.
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OBJECTIVE: Treatment with LJP 394 results in decreased
ÁdsDNA Ab in patients with SLE. Sustained reductions were
demonstrated in 2 RCTs of 298 [phase 3] and 189 [phase 2/3]
SLE patients with a history of renal disease, statistically favor-
ing active vs placebo treatment. SF-36 was assessed at baseline,
6 and 12 months in phase 3 to evaluate the impact of sustained
reductions on patient reported HRQOL. METHODS: Sustained
reductions: ≥20% decreases from baseline in ≥2/3 of all ÁdsDNA
Ab determinations deﬁned “responders”. Minimal clinically
important differences [MCID] were based on a 15-point global
change scale. RESULTS: In phase 3, 31.4% patients were respon-
ders, 63 in LJP394, 28 in placebo; a ratio of 2.25 favoring active
treatment. At 6 months, 31.3% were responders: 59 LJP394 and
27 placebo; a ratio of 2.2. At 6 months, responders reported
improvement in all domains of SF-36 with the largest increases
in bodily pain (8.2), vitality (8.0), general health perceptions
(6.6) and physical function (5.7). Non-responders reported wors-
ening in all but 3 domains, which remained unchanged (vitality
(1.3), mental health (0.9), and role emotional (0.0)). At 12
months, 43 LJP394 and 24 placebo treated patients were respon-
ders; a ratio of 1.8; 35.3% overall. Improvements reported by
responders increased by month 12, with largest changes in role
physical (13.8), vitality (10.2), general health proﬁle (9.3), and
bodily pain (7.3), again with no change or deterioration in non-
responders. Improvements in domain scores were reﬂected in
physical component summary [PCS] score. MCID was deter-
mined to range from 6.7 to 11.4 points in domain and 3.4 to
3.9 in PCS scores, consistent with literature reported estimates
of 5–10 and 2.5–5.0 points. CONCLUSION: Sustained reduc-
tions in ÁdsDNA Ab levels lead to improvement in patient
reported HRQOL. These improvements are clinically meaning-
ful, regardless of treatment group. LJP394 administration
resulted in 1.8 to 4.0 times more responders than placebo.
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OBJECTIVE: To describe an evaluation of isotretinoin prescrib-
ing patterns before and after implementation of the System to
Manage Accutane-Related Teratogenicity (SMART), a risk man-
agement plan developed by Hoffmann-LaRoche to minimize the
risk of pregnancy among women taking Accutane. METHODS:
The IMS Health, National Prescription Audit Plus provided
information on the number of prescriptions dispensed for the
pre- (1 April 2001–31 March 2002) and post- (1 April 2002–31
March 2003) SMART periods. Data on patient gender, pre-
scriber speciality, and physician-reported severity of indication
for use were obtained from AdvancePCS, a large pharmacy 
beneﬁts manager (PBM), and the IMS Health, National Disease
and Therapeutic Index. RESULTS: In the 12-months prior 
to SMART, 1,508,000 prescriptions were dispensed for
isotretinoin; declining approximately 23% to 1,160,000 pre-
scriptions in the year following SMART. Dermatologists were 
the most common prescribers of isotretinoin, accounting for
76% and 80% of the prescriptions dispensed in the year 
before and after SMART, respectively. Half of the claims for
isotretinoin were for females in both the pre- and post-SMART
eras. The severity of indication for use did not appear to be
affected by SMART. In the year pre-SMART, 53% of the
isotretinoin mentions during ofﬁce visits for female patients were
for “severe” acne cases, compared to 55% in the year post-
SMART. Similar percentages were seen for males. CONCLU-
SIONS: SMART may have inﬂuenced the number of isotretinoin
prescriptions dispensed, but appeared to have little impact on
other variables such as prescriber speciality and severity of indi-
cation for use.
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OBJECTIVES: To examine the effects of initial ziprasidone dose
on discontinuation rates, using the PharMetrics integrated
medical and pharmacy claims data. METHODS: Patients ≥18
years with a diagnosis of schizophrenia and a ziprasidone claim
between March 2001 and February 2003 continuously enrolled
for ≥6 months before and ≥3 months after initiation of ziprasi-
done were stratiﬁed by initial daily dose (≥40mg and <80mg
[low] vs. ≥80mg and <120mg [medium] vs. 120mg–160mg
[high]). The 6-month risk of discontinuation was examined using
Cox proportional hazards models controlling for gender, psy-
chiatric comorbidities, and pre-ziprasidone utilization of antipsy-
chotics (atypical, conventional, none). RESULTS: Mean age of
the sample (n = 1058) was 38 years; 42% were male. The 
6-month risk of discontinuation was signiﬁcantly greater in
patients with a low vs high initial dose (HR = 1.357, 95% CI =
1.070, 1.721; p = 0.012) and trended towards signiﬁcance when
comparing a medium vs high initial dose (HR = 1.163, 95% 
CI = 0.905, 1.494; p = 0.237). The largest difference in discon-
tinuation rates between dose groups occurred after the ﬁrst 
prescription. CONCLUSIONS: Patients initiating ziprasidone
therapy with an initial dose of at least 120mg/day had better
medication adherence compared with those initiating at lower
doses. This may reﬂect improved efﬁcacy at daily doses ≥120mg.
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